Navigation Links
FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis

Food and Drug Association as approved the drug CLARINEX-D 12 HOUR for use in treating symptoms of seasonal allergic rhinitis. // CLARINEX-D 12 HOUR is a drug containing a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg. FDA has approved the drug for use in persons above 12 years of age. The drug has been found effective in curing persons with nasal and non-nasal symptoms occurring due to seasonal allergic rhinitis. Two clinical studies in 1,248 patients have found that the drug CLARINEX-D is found to be more effective in controlling allergic symptoms than the drug psueoephedrine alone.

The drug contains a delivery system, which delivers psudoephedrine in a consistent manner, and a dosage of two times a day of the nasal drug is found to be effective in controlling symptoms of allergic rhinitis and relieves nasal blockage and congestion, running nose, sneezing, watery eyes and itchy throat. The drug is found to be very effective in controlling allergic symptoms but has been found to be associated with mild side effects of insomnia, headache, pharyngitis, weakness and fatigue.


'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves drug for rare liver disease
4. FDA approves first pocket-sized EKG machine
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
7. Madras High Court Disapproves of Comparative Advertisements
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Old flu drugs not effective against seasonal influenza
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a ... Miami, and Raleigh regions, is organizing an extended charity drive to benefit the ... chromosome abnormality. , After struggling since birth with several health challenges, T.J. was ...
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
Breaking Medicine Technology: